NICE: Real-World Evidence Revolution Will Drive UK’s Health Care Innovation
Decision-makers will have more data on which to judge the value of innovative medtech and healthtech products
Executive Summary
In its just-released real-world evidence framework, NICE assesses the role and value of data collected outside highly-controlled clinical studies in driving more innovation towards health care professionals.
You may also be interested in...
Here Comes The NICE Revolution – Agility And Speed Will Drive UK HTA Into A New Era
Evolving health care demands, digital innovation and the need to work within tighter budgets have prompted the UK’s NICE to reset its strategy for the coming five years.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.